Details

Autor(en) / Beteiligte

• KYLE, R. A
• DURIE, B. G. M
• SAN MIGUEL, J
• AVET-LOISEAU, H
• HAJEK, R
• CHEN, W. M
• ANDERSON, K. C
• LUDWIG, H
• SONNEVELD, P
• PAVLOVSKY, S
• PALUMBO, A
• RICHARDSON, P. G
• RAJKUMAR, S. V
• BARLOGIE, B
• GREIPP, P
• VESCIO, R
• TURESSON, I
• WESTIN, J
• BOCCADORO, M
• LANDGREN, O
• BLADE, J
• MERLINI, G
• KRÖGER, N
• EINSELE, H
• VESOLE, D. H
• DIMOPOULOS, M

Titel

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Ist Teil von

• Leukemia, 2010-06, Vol.24 (6), p.1121-1127

Ort / Verlag

Avenel, NJ: Nature Publishing Group

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein <15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months.